Features Partner Sites Information LinkXpress
Sign In
Demo Company

Bead-Based Capture Kit Eases Enrichment and Cleanup of DNA Libraries

By BiotechDaily International staff writers
Posted on 13 Jun 2013
Print article
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
A newly released bead-based capture system was designed to provide genomic researchers with a sensitive and robust method for capture and purification of DNA sample libraries enabling high-quality targeted sequencing results.

NimbleGen (Madison, WI, USA), the genomics products subsidiary of Roche (Basel, Switzerland), recently announced the global launch of its SeqCap EZ Pure Capture Bead Kit.

This kit offers researchers a set of capture and purification beads used to prevent secondary capture and isolate DNA sample libraries from contaminants during amplification. It, therefore, represents a sensitive and robust method for cleanup of DNA sample libraries for high-quality DNA sequencing results

The kit includes SeqCap EZ Capture Beads and SeqCap EZ Purification Beads. Capture beads are used to recover the captured DNA sample from the hybridization of the DNA sample library and the SeqCap EZ Library. Purification beads are used to purify the amplified DNA sample library and the amplified capture DNA sample library after LM-PCR (ligase mediated - polymerase chain reaction). Roche provides a comprehensive set of reagents and probe pools for superior target enrichment performance. The probe pools include exome libraries, gene panels, and custom designs.

In addition to the SeqCap EZ Capture Beads Kit, Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.

Related Links:


Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.